Gain-of-Function Mutant p53 Promotes Cell Growth and Cancer Cell Metabolism via Inhibition of AMPK Activation

Molecular Cell

Volumn 54, Issue 6, 2014, Pages 960-974

  Zhou, Ge ^a   Wang, Jiping ^a   Zhao, Mei ^a   Xie, Tong Xin ^a   Tanaka, Noriaki ^a   Sano, Daisuke ^a   Patel, Ameeta A ^a   Ward, Alexandra M ^a   Sandulache, Vlad C ^a   Jasser, Samar A ^a   Skinner, Heath D ^a   Fitzgerald, Alison Lea ^a   Osman, Abdullah A ^a   Wei, Yongkun ^a   Xia, Xuefeng ^a,b   Songyang, Zhou ^c,d   Mills, Gordon B ^a   Hung, Mien Chie ^a,e   Caulin, Carlos ^a   Liang, Jiyong ^a   Myers, Jeffrey N ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d SUN YAT SEN UNIVERSITY   (China)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; AMP ACTIVATED PROTEIN KINASE ALPHA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MUTANT PROTEIN; PROTEIN P53; PROTEIN S6; UNCLASSIFIED DRUG;

AEROBIC CAPACITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL LINE; CANCER CELL METABOLISM; CELL GROWTH; CELL METABOLISM; CONTROLLED STUDY; DOWN REGULATION; ENERGY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBUNIT; GAIN OF FUNCTION MUTATION; GLYCOLYSIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WILD TYPE;

ACETYL-COA CARBOXYLASE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; CELL PROLIFERATION; ENERGY METABOLISM; ENZYME ACTIVATION; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROTEIN BINDING; RIBOSOMAL PROTEIN S6; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84903627732     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2014.04.024     Document Type: Article

References (47)

1. Acin S., Li Z., Mejia O., Roop D.R., El-Naggar A.K., Caulin C. Gain-of-function mutant p53 but not p53 deletion promotes head and neckcancer progression in response to oncogenic K-ras. J.Pathol. 2011, 225:479-489.
2. Agrawal N., Frederick M.J., Pickering C.R., Bettegowda C., Chang K., Li R.J., Fakhry C., Xie T.X., Zhang J., Wang J., et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011, 333:1154-1157.
3. Berkers C.R., Maddocks O.D., Cheung E.C., Mor I., Vousden K.H. Metabolic regulation by p53 family members. Cell Metab. 2013, 18:617-633.
4. Bertout J.A., Patel S.A., Fryer B.H., Durham A.C., Covello K.L., Olive K.P., Goldschmidt M.H., Simon M.C. Heterozygosity for hypoxia inducible factor 1alpha decreases the incidence of thymic lymphomas in a p53 mutant mouse model. Cancer Res. 2009, 69:3213-3220.
5. Budanov A.V., Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 2008, 134:451-460.
6. DeBerardinis R.J., Thompson C.B. Cellular metabolism and disease: what do metabolic outliers teach us?. Cell 2012, 148:1132-1144.
7. Esfandiari F., You M., Villanueva J.A., Wong D.H., French S.W., Halsted C.H. S-adenosylmethionine attenuates hepatic lipid synthesis in micropigs fed ethanol with a folate-deficient diet. Alcohol. Clin. Exp. Res. 2007, 31:1231-1239.
8. Faubert B., Boily G., Izreig S., Griss T., Samborska B., Dong Z., Dupuy F., Chambers C., Fuerth B.J., Viollet B., et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth invivo. Cell Metab. 2013, 17:113-124.
9. Feng Z., Levine A.J. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol. 2010, 20:427-434.
10. Feng Z., Hu W., de Stanchina E., Teresky A.K., Jin S., Lowe S., Levine A.J. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 2007, 67:3043-3053.
11. Fogarty S., Hardie D.G. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim. Biophys. Acta 2010, 1804:581-591.
12. Freed-Pastor W.A., Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012, 26:1268-1286.
13. Freed-Pastor W.A., Mizuno H., Zhao X., Langerød A., Moon S.H., Rodriguez-Barrueco R., Barsotti A., Chicas A., Li W., Polotskaia A., et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012, 148:244-258.
14. Goldstein I., Rotter V. Regulation of lipid metabolism by p53-fighting two villains with one sword. Trends Endocrinol. Metab. 2012, 23:567-575.
15. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
16. Hardie D.G. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011, 25:1895-1908.
17. Hardie D.G., Pan D.A. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem. Soc. Trans. 2002, 30:1064-1070.
18. Hardie D.G., Ross F.A., Hawley S.A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 2012, 13:251-262.
19. Hawley S.A., Davison M., Woods A., Davies S.P., Beri R.K., Carling D., Hardie D.G. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J.Biol. Chem. 1996, 271:27879-27887.
20. He G., Zhang Y.W., Lee J.H., Zeng S.X., Wang Y.V., Luo Z., Dong X.C., Viollet B., Wahl G.M., Lu H. AMP-activated protein kinase induces p53 by phosphorylating MDMX and inhibiting its activity. Mol. Cell. Biol. 2014, 34:148-157.
21. Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., Thompson C.B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 2005, 18:283-293.
22. Kamat C.D., Green D.E., Warnke L., Thorpe J.E., Ceriello A., Ihnat M.A. Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. Cancer Lett. 2007, 249:209-219.
23. Kodiha M., Rassi J.G., Brown C.M., Stochaj U. Localization ofAMP kinase is regulated by stress, cell density, and signaling through the MEK→ERK1/2 pathway. Am. J. Physiol. Cell Physiol. 2007, 293:C1427-C1436.
24. Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119:861-872.
25. Lee C.W., Wong L.L., Tse E.Y., Liu H.F., Leong V.Y., Lee J.M., Hardie D.G., Ng I.O., Ching Y.P. AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. Cancer Res. 2012, 72:4394-4404.
26. Li Y., Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?. Oncogene 2007, 26:2220-2225.
27. Li Y., Xu S., Mihaylova M.M., Zheng B., Hou X., Jiang B., Park O., Luo Z., Lefai E., Shyy J.Y., et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 2011, 13:376-388.
28. Luo Z., Zang M., Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol. 2010, 6:457-470.
29. Mihaylova M.M., Shaw R.J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 2011, 13:1016-1023.
30. Morselli E., Tasdemir E., Maiuri M.C., Galluzzi L., Kepp O., Criollo A., Vicencio J.M., Soussi T., Kroemer G. Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle 2008, 7:3056-3061.
31. Muller P.A., Vousden K.H. p53 mutations in cancer. Nat. Cell Biol. 2013, 15:2-8.
32. Nicholls D.G., Darley-Usmar V.M., Wu M., Jensen P.B., Rogers G.W., Ferrick D.A. Bioenergetic profile experiment using C2C12 myoblast cells. J. Vis. Exp 2010, 10.3791/2511.
33. Okoshi R., Ozaki T., Yamamoto H., Ando K., Koida N., Ono S., Koda T., Kamijo T., Nakagawara A., Kizaki H. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J.Biol. Chem. 2008, 283:3979-3987.
34. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., Crowley D., Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119:847-860.
35. Oren M., Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2010, 2:a001107.
36. Sano D., Xie T.X., Ow T.J., Zhao M., Pickering C.R., Zhou G., Sandulache V.C., Wheeler D.A., Gibbs R.A., Caulin C., Myers J.N. Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer. Clin. Cancer Res. 2011, 17:6658-6670.
37. Shackelford D.B., Shaw R.J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 2009, 9:563-575.
38. Solomon H., Buganim Y., Kogan-Sakin I., Pomeraniec L., Assia Y., Madar S., Goldstein I., Brosh R., Kalo E., Beatus T., et al. Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature. J.Cell Sci. 2012, 125:3144-3152.
39. Stommel J.M., Marchenko N.D., Jimenez G.S., Moll U.M., Hope T.J., Wahl G.M. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 1999, 18:1660-1672.
40. Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., Kryukov G.V., Lawrence M.S., Sougnez C., McKenna A., et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-1160.
41. Su X., Gi Y.J., Chakravarti D., Chan I.L., Zhang A., Xia X., Tsai K.Y., Flores E.R. TAp63 is a master transcriptional regulator of lipid and glucose metabolism. Cell Metab. 2012, 16:511-525.
42. Tsou P., Zheng B., Hsu C.H., Sasaki A.T., Cantley L.C. A fluorescent reporter of AMPK activity and cellular energy stress. Cell Metab. 2011, 13:476-486.
43. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
44. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21:297-308.
45. Winder W.W., Wilson H.A., Hardie D.G., Rasmussen B.B., Hutber C.A., Call G.B., Clayton R.D., Conley L.M., Yoon S., Zhou B. Phosphorylation of rat muscle acetyl-CoA carboxylase by AMP-activated protein kinase and protein kinase A. J.Appl. Physiol. 1997, 82:219-225.
46. Xu J., Reumers J., Couceiro J.R., De Smet F., Gallardo R., Rudyak S., Cornelis A., Rozenski J., Zwolinska A., Marine J.C., et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat. Chem. Biol. 2011, 7:285-295.
47. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12:21-35.